These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 25981655

  • 1. [Successful treatment of relapsed and refractory multiple myeloma by using clarithromycin-lenalidomide, low-dose dexamethasone(BiRd), and melphalan-prednisolone(MP)].
    Tsunemine H, Yoshioka S, Sakane E, Akasaka H, Ito K, Kodaka T, Takahashi T.
    Gan To Kagaku Ryoho; 2015 May; 42(5):605-7. PubMed ID: 25981655
    [Abstract] [Full Text] [Related]

  • 2. Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin.
    Holmberg LA, Becker PS, Bensinger W.
    Acta Haematol; 2017 May; 137(3):123-131. PubMed ID: 28355602
    [Abstract] [Full Text] [Related]

  • 3. Oral melphalan, dexamethasone, and thalidomide for the treatment of refractory multiple myeloma.
    Asou N, Izuno Y, Okubo T, Ide K, Ueno H, Kawakita M, Mitsuya H, Hata H.
    Int J Hematol; 2007 Jul; 86(1):69-71. PubMed ID: 17675270
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Chemotherapy for multiple myeloma].
    Ishida T.
    Nihon Rinsho; 2007 Dec; 65(12):2280-4. PubMed ID: 18069273
    [Abstract] [Full Text] [Related]

  • 8. [Effective BiRd Therapy after the Addition of Clarithromycin for Lenalidomide and Dexamethasone Resistant Multiple Myeloma Ineligible for Stem Cell Transplantation].
    Miura S, Kuroda H, Yamada M, Sato K, Ameda S, Sakano H, Shibata T, Uemura N, Abe T, Fujii S, Maeda M, Kobune M, Kato J.
    Gan To Kagaku Ryoho; 2017 Aug; 44(8):689-693. PubMed ID: 28860442
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.
    Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S, Jalbrzikowski J, Pearse RN, Zafar F, Pekle K, Larow A, Lent R, Mark T, Cho HJ, Shore T, Tepler J, Harpel J, Schuster MW, Mathew S, Leonard JP, Mazumdar M, Chen-Kiang S, Coleman M.
    Blood; 2008 Feb 01; 111(3):1101-9. PubMed ID: 17989313
    [Abstract] [Full Text] [Related]

  • 11. Addition of clarithromycin to lenalidomide/low-dose dexamethasone was effective in a case of relapsed myeloma after long-term use of lenalidomide.
    Kato H, Onishi Y, Okitsu Y, Katsuoka Y, Fujiwara T, Fukuhara N, Ishizawa K, Takagawa M, Harigae H.
    Ann Hematol; 2013 Dec 01; 92(12):1711-2. PubMed ID: 23625297
    [No Abstract] [Full Text] [Related]

  • 12. BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma.
    Rossi A, Mark T, Jayabalan D, Christos P, Zafar F, Pekle K, Pearse R, Chen-Kiang S, Coleman M, Niesvizky R.
    Blood; 2013 Mar 14; 121(11):1982-5. PubMed ID: 23299315
    [Abstract] [Full Text] [Related]

  • 13. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
    Delforge M, Michiels A, Doyen C, Kentos A, Van Droogenbroeck J, Offner F, Bries G, Demuynck H, Vekemans MC, Meuleman N, Mineur PO, Ravoet C, Depryck B, Van de Velde A, Pierre P, Wu KL, Schots R.
    Acta Clin Belg; 2011 Mar 14; 66(5):371-5. PubMed ID: 22145272
    [Abstract] [Full Text] [Related]

  • 14. A novel combination of bortezomib, lenalidomide, and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus - clinical significance and possible mechanisms: a case report.
    Takemori N, Imai G, Hoshino K, Ooi A, Kojima M.
    J Med Case Rep; 2018 Feb 18; 12(1):40. PubMed ID: 29454372
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma.
    Palumbo A, Avonto I, Bruno B, Falcone A, Scalzulli PR, Ambrosini MT, Bringhen S, Gay F, Rus C, Cavallo F, Falco P, Massaia M, Musto P, Boccadoro M.
    Clin Lymphoma Myeloma; 2006 May 18; 6(6):475-7. PubMed ID: 16796778
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation.
    Moreau P, Hulin C, Facon T.
    Hematol Oncol Clin North Am; 2014 Oct 18; 28(5):829-38. PubMed ID: 25212885
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.